AU2006209547C1 - Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor - Google Patents

Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor Download PDF

Info

Publication number
AU2006209547C1
AU2006209547C1 AU2006209547A AU2006209547A AU2006209547C1 AU 2006209547 C1 AU2006209547 C1 AU 2006209547C1 AU 2006209547 A AU2006209547 A AU 2006209547A AU 2006209547 A AU2006209547 A AU 2006209547A AU 2006209547 C1 AU2006209547 C1 AU 2006209547C1
Authority
AU
Australia
Prior art keywords
cancer
ftd
day
dose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006209547A
Other languages
English (en)
Other versions
AU2006209547B2 (en
AU2006209547A1 (en
Inventor
Tomohiro Emura
Akira Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006209547(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2006209547A1 publication Critical patent/AU2006209547A1/en
Application granted granted Critical
Publication of AU2006209547B2 publication Critical patent/AU2006209547B2/en
Publication of AU2006209547C1 publication Critical patent/AU2006209547C1/en
Assigned to LES LABORATORIES SERVIER reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: TAIHO PHARMACEUTICAL CO., LTD.
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006209547A 2005-01-26 2006-01-25 Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor Active AU2006209547C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US11/042,059 2005-01-26
JP2005-165156 2005-06-06
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (3)

Publication Number Publication Date
AU2006209547A1 AU2006209547A1 (en) 2006-08-03
AU2006209547B2 AU2006209547B2 (en) 2011-05-26
AU2006209547C1 true AU2006209547C1 (en) 2022-04-07

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006209547A Active AU2006209547C1 (en) 2005-01-26 2006-01-25 Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Country Status (21)

Country Link
EP (1) EP1849470B2 (show.php)
JP (1) JP5576591B2 (show.php)
KR (1) KR101468216B1 (show.php)
AU (1) AU2006209547C1 (show.php)
BE (1) BE2017C028I2 (show.php)
CA (1) CA2594713A1 (show.php)
CY (2) CY1119393T1 (show.php)
DK (1) DK1849470T4 (show.php)
ES (1) ES2630002T5 (show.php)
FI (1) FI1849470T4 (show.php)
FR (1) FR17C1028I2 (show.php)
HU (2) HUE033306T2 (show.php)
LT (2) LT1849470T (show.php)
LU (1) LUC00036I2 (show.php)
NL (1) NL300889I2 (show.php)
PL (1) PL1849470T5 (show.php)
PT (1) PT1849470T (show.php)
RU (1) RU2394581C2 (show.php)
SI (1) SI1849470T2 (show.php)
TW (1) TWI362265B (show.php)
WO (1) WO2006080327A1 (show.php)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2008132443A1 (en) 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
DK2273983T3 (en) 2008-05-09 2016-09-19 Gruenenthal Gmbh A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
TW201105316A (en) 2009-07-22 2011-02-16 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
JP5925779B2 (ja) 2010-09-02 2016-05-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 無機塩を含む不正使用抵抗性剤形
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
PL2746404T3 (pl) 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
AU2013233226B2 (en) 2012-03-14 2016-05-19 Nisshin Pharma Inc. Sulfur amino acid-containing composition
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
RU2668125C2 (ru) * 2013-03-27 2018-09-26 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
ES2824400T3 (es) * 2013-03-27 2021-05-12 Taiho Pharmaceutical Co Ltd Agente antitumoral que incluye clorhidrato de irinotecán hidratado
WO2014185528A1 (ja) * 2013-05-17 2014-11-20 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
CA2917136C (en) 2013-07-12 2022-05-31 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
DK3042669T3 (da) 2013-09-06 2023-06-12 Taiho Pharmaceutical Co Ltd Antitumormiddel og forstærker af antitumorvirkning
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
AU2017205531B2 (en) 2016-01-08 2021-05-13 Les Laboratoires Servier Anti-tumor agent containing immunomodulator and anti-tumor effect potentiator
EP3412295A4 (en) * 2016-02-05 2019-09-25 Taiho Pharmaceutical Co., Ltd. METHOD FOR THE TREATMENT OF CANCER PATIENTS WITH HEAVY NIER FUNCTION TROUBLESHOOTING
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013045A1 (en) * 1996-09-24 1998-04-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US6294535B1 (en) * 1995-03-29 2001-09-25 Taiho Pharmaceutical Co., Ltd. Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same

Also Published As

Publication number Publication date
LT1849470T (lt) 2017-07-25
HUS1700032I1 (hu) 2017-09-28
LTC1849470I2 (lt) 2019-10-25
CY2017029I1 (el) 2018-02-14
EP1849470B2 (en) 2024-03-20
ES2630002T3 (es) 2017-08-17
PL1849470T5 (pl) 2024-06-10
DK1849470T3 (en) 2017-08-14
CA2594713A1 (en) 2006-08-03
NL300889I2 (nl) 2018-01-16
BE2017C028I2 (show.php) 2025-09-10
KR20070104559A (ko) 2007-10-26
AU2006209547B2 (en) 2011-05-26
EP1849470A4 (en) 2010-12-08
TW200637562A (en) 2006-11-01
SI1849470T2 (sl) 2024-05-31
RU2007132181A (ru) 2009-03-10
NL300889I1 (nl) 2017-08-14
HUE033306T2 (hu) 2017-11-28
EP1849470A1 (en) 2007-10-31
FI1849470T4 (fi) 2024-03-22
TWI362265B (en) 2012-04-21
LTPA2017024I1 (lt) 2017-08-10
JPWO2006080327A1 (ja) 2008-06-19
KR101468216B1 (ko) 2014-12-03
JP5576591B2 (ja) 2014-08-20
AU2006209547A1 (en) 2006-08-03
CY2017029I2 (el) 2018-02-14
CY1119393T1 (el) 2018-02-14
SI1849470T1 (sl) 2017-10-30
RU2394581C2 (ru) 2010-07-20
ES2630002T5 (es) 2024-09-19
FR17C1028I1 (show.php) 2017-09-29
LUC00036I2 (show.php) 2017-12-01
LUC00036I1 (show.php) 2017-10-02
PL1849470T3 (pl) 2017-11-30
PT1849470T (pt) 2017-09-22
EP1849470B1 (en) 2017-06-21
FR17C1028I2 (fr) 2018-11-02
WO2006080327A1 (ja) 2006-08-03
DK1849470T4 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
AU2006209547C1 (en) Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 DEC 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 03 DEC 2021

PC Assignment registered

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER OWNER(S): TAIHO PHARMACEUTICAL CO., LTD.